The NOX inhibitor platform has developed a high-level hNOX separation technology using Drosophila and by using this technology we have developed into a high-speed mass screening (HTS) system based on the world’s first hNOX activity By expressing the each hNOX enzymes (NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1, and DUOX2) in the Drosophila line, selectivity and specificity are increased so that enables to screen the compounds quickly and cost effectively.

In general, under consistent hyperglycemic and hypertensive condition, overexpression of NOX enzyme result in excessive production of reactive oxygen species (ROS), causing oxidative stress and tissue damage.

Our APX derivatives effectively inhibit NOX overexpression, thereby regulating the production of ROS, which has the mechanism to treat diabetic complications such as diabetic nephropathy, diabetic retinopathy, macular degeneration, NASH, and arteriosclerosis.